Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.51 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12646449 | 0.84 | SLC6A3 (0.46) | FFAR1FFAR4LTB4R2 | |
| SCHEMBL12646566 | 0.83 | FFAR1 (0.81) | FFAR1KEAP1FFAR4PTGER1PTGER4 | |
| SCHEMBL1510067 | 0.81 | FFAR1 (0.66) | FFAR1KEAP1FFAR4PTGER1PTGER4 | |
| SCHEMBL1515723 | 0.79 | BCAT2 (0.59) | LTB4R2 | |
| SCHEMBL12646564 | 0.79 | FFAR1 (0.67) | FFAR1KEAP1FFAR4PTGER1PTGER4 | |
| SCHEMBL294730 | 0.79 | BCAT2 (0.63) | — | |
| SCHEMBL31125227 | 0.79 | BCAT2 (0.63) | — | |
| SCHEMBL10449002 | 0.79 | BRS3 (0.46) | LTB4R2 | |
| SCHEMBL14132409 | 0.79 | LTB4R2 (0.49) | LTB4R2 | |
| SCHEMBL27431910 | 0.79 | LTB4R2 (0.49) | LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | SYDDANSK UNIVERSITET | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152315-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | GPR119, INSR, GPR65 | FFAR1 6/4885KEAP1 1257/4885FFAR4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.